PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsNeuroscienceParkinson's
  • Spectramax light therapy can be a potential treatment for Parkinson’s disease

    • October 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Smartphones can be used to detect Parkinson’s symptoms early, research says

    • October 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • New Drug Candidate identified for Parkinson’s Disease

    • September 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Positive Clinical Results announced for LRRK2 in Parkinson’s Disease

    • August 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Herantis initiates CDNF development program for Parkinson’s disease

    • July 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • MANF Therapeutics announces positive data in Parkinson’s model

    • July 10, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Titan postpones Parkinson’s implant trial program

    • July 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Neupro approved in China to treat Parkinson’s disease

    • July 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Hypertension drug shows positive Ph 3 Parkinson’s results in mice

    • July 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • New dose formulation for Nuplazid, in Parkinsons, approved by FDA

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • 1
  • 2
  • 3
  • 4
Recent Posts
  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare
  • Social Media Analytics in Healthcare

Contact Us

  • Indian Address: PharmaScroll Research and Consulting Private Limited, 91 Springboard, 4th floor, F948+W7, Laxmi Cyber City, Whitefields, Hyderabad, Telangana 500081
  • US address: 12 Self Ct, Wallingford CT 06492
  • +919311760222
  • enquiry@pharmascroll.com

Recent Tweets

  • Discover potential KOLs and explore the network maps of these KOLs with TreasureTell. Contact us for a demo: enqui… https://t.co/lC0jqVxxa02 days ago
  • The FDA has approved Tafinlar with Mekinist for the treatment of pediatric patients 1 year of age and older with lo… https://t.co/h5uRCFGRTl6 days ago

Recent Posts

  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry

News Letter

© 2023 Copyright. All rights reserved